Pharma News India Weekly (10 May – 16 May 2026): GLP-1 Market Explodes, Chemist Strike Confirmed & Assam Opts Out

Published By: Greencrossindia.com updated with the modern happenings inside the Indian pharma enterprise! Our weekly roundup highlights key tendencies, innovations, and developments from May 10-16, 2026.

Namaste Readers!

Welcome again for your weekly dose of Pharma News India Weekly.

The week of May 10 to May 16, 2026, became actually packed with trends. The GLP-1 weight loss drug market in India exploded with top notch boom, the national chemist strike on May 20 became finalized, but in a shocking twist, Assam chemists decided to decide out of the bandh.

So clutch your cup of chai ☕ and permit me walk you thru the modern-day pharmaceutical information in India in easy and smooth language.

For more such weekly updates, keep journeying Greencrossindia.com/blog.

Quick Highlights: Pharma News India This Week

Let me speedy list the top 18 stories we're protecting these days:

1. GLP-1 weight-loss drug sales surged fifty one% in April -- marketplace now ₹1,800 crore+

2. Over 137,000 units of prevalent semaglutide offered in April -- a 242% jump

3. Innovator brands held their floor with forty% quantity increase in spite of universal flood

4. Mounjaro keeps to dominate with 55% marketplace percentage

5. Torrent Pharmaceuticals leads everyday semaglutide race with 38% share

6. Nationwide chemist strike on May 20 showed -- over 12 lakh shops to stay closed

7. Assam chemists determined to choose out -- pharmacies will stay open inside the country

8. Telangana chemists showed participation inside the nationwide shutdown

9. Karnataka chemists be a part of strike, hospitals and clinical pharmacies exempted

10. AIOCD demands withdrawal of GSR 817 and GSR 220 notifications

11. Concerns raised over AI-generated faux prescriptions and antimicrobial resistance

12. India pharma exports: $30.4 Bn in FY25, USA and Europe biggest locations

13. India debts for 20% of world universal deliver, 60% of global vaccines

14. 500+ APIs synthetic in India, 31% of worldwide API manufacturing flowers

15. Former FDA Commissioner Marty Makary resigns after key regulatory shifts

16. FDA approves once-weekly insulin, high-dose semaglutide, and oral psoriasis drug

17. M&A hobby surges as Indian pharma eyes global area of expertise expansion

18. Quality manipulate and regulatory harmonization continue to be key industry challenges

APPLY FOR PCD PHARMA FRANCHISE

Let me explain each tale in simple phrases.

Overview of the Indian Pharma Industry

Before we dive into the weekly information, allow me come up with a short evaluate of in which the Indian pharmaceutical enterprise stands these days.

India's pharmaceutical zone is driven through a robust clinical and technological base, leading globally as the biggest vaccine producer, accounting for ~60% of world vaccine manufacturing and providing to over a hundred and fifty nations.

Major segments of the pharma zone in India encompass conventional pills, OTC medicines, bulk drugs, vaccines, agreement studies and manufacturing, biosimilars, and biologics.

Key enterprise records:

Exports: $30.4 billion in FY 2024-25, with the USA and Europe being the largest export locations

Imports: $8.9 billion, resulting in a positive trade balance of $21.5 billion

Global conventional supply: India money owed for 20% of worldwide typical drug treatments

API manufacturing: 500+ APIs synthetic, 31% of world API production plant life are in India

Vaccine powerhouse: 60% of world vaccine call for fulfilled, imparting to one hundred fifty+ countries

Clinical trials: 94,000+ medical trials registered by using 2025, India is the 3rd most preferred destination globally

With 9 of the world's top 25 universal manufacturers being Indian, India produces 60,000 well-known manufacturers across 60 healing classes. Exports span 200+ nations, with the majority of exports falling under drug formulations and biologicals.

1. GLP-1 Weight-Loss Drug Market Explodes in India

The biggest news this week in Pharma News India Weekly is the splendid surge in GLP-1 weightloss drug sales throughout India.

According to statistics from market studies company Pharmarack, the injectable GLP-1 remedy market has increased tenfold over the past 12 months, from around ₹a hundred and forty crore in April final year to approximately ₹1,408 crore now.

What happened in April 2026?

Semaglutide sales climbed about fifty one consistent with cent month-on-month to ₹88 crore in April 2026, up from ₹fifty eight crore in March. The contribution of semaglutide to the GLP-1 marketplace elevated to forty in keeping with cent in April, from 33 consistent with cent in March.

What about Mounjaro?

Mounjaro keeps to dominate the GLP-1 marketplace with a 55 in keeping with cent proportion. In October last year, Mounjaro became India's pinnacle-promoting medicinal drug logo -- a role it has retained since, no matter being the maximum high-priced drug inside the section, ranging from ₹thirteen,125 to over ₹25,000 according to month relying at the dose electricity.

Mounjaro registered 10 in keeping with cent volume boom in April as compared to March, despite well-known opposition inside the phase.

The extent explosion

Let me percentage a few eye-beginning numbers.

Around 137,000 units of well-known semaglutide were sold in April 2026 -- that could be a 242 per cent rise from the forty,000 gadgets bought in March.

But here is the thrilling element. Innovator molecules along with Ozempic and Wegovy also witnessed an growth of round 39 according to cent -- from 23,000 gadgets sold in March to 32,000 gadgets in April. This got here after Novo Nordisk slashed starting-dose costs by way of 36% and 48% respectively from April 1, bringing each pills down to ₹5,660 in keeping with month.

What do specialists say?

Sheetal Sapale, vice chairman (industrial) at Pharmarack, instructed Bloomberg News: The competitive pricing "helped increase affordability" and allowed the Danish drugmaker to protect its marketplace proportion in opposition to less expensive competitors. The increase indicates Novo Nordisk -- together with Eli Lilly -- will remain the "desired desire for a class of sufferers and doctors."

Why are innovators holding their ground?

Dr Sukhvinder Singh Saggu, director for minimal get admission to, gastrointestinal and bariatric surgical procedure at Delhi's C K Birla Hospital, explained that standard formulations can on occasion contain more complicated or larger molecules, which might also have an effect on how efficaciously they paintings in the body. If the molecule does now not efficiently cross the blood-mind barrier, its movement at the hypothalamus may not be as strong.

Simple knowledge

What does this mean? Let me wreck it down.

More than 25 standard versions of semaglutide entered the market at once after the molecule's patent expiry in March. This has made weight-loss capsules much more lower priced -- conventional versions are priced as little as $14 for a monthly dose. More patients can now get entry to these drug treatments.

But at the equal time, many medical doctors and sufferers nevertheless opt for innovator manufacturers. They agree with the authentic products greater. They agree with the efficacy and bioavailability of generics can be relatively decrease.

So the market is now cut up -- generics are developing speedy in extent, but innovators are conserving their sales floor. Total sales volume of GLP-1 remedies grew fifty six% month-on-month to 414,000 devices in April.

2. Torrent Pharmaceuticals Leads Generic Semaglutide Race

Among the common players, Ahmedabad-primarily based Torrent Pharmaceuticals has emerged because the clean chief.

The state-of-the-art Pharmarack report suggests that Torrent has maintained its lead within the regularly occurring semaglutide marketplace with a 38 in line with cent proportion.

Out of almost 25 popular semaglutide brands now to be had within the market, Torrent's Semalix and Sembolic amassed ₹17 crore in sales final month.

Other businesses which includes Eris, Alkem, MSN and Corona Pharma additionally picked up market share in April. The semaglutide variations by means of Lupin, Zydus and Dr Reddy's trailed Torrent's copies, amassing around ₹4 crore every in income closing month.

Pharmarack stated that competitive efforts are being visible by generics gamers to make the maximum of the opportunity, but handiest new launches were visible within the month of April -- with most conventional variations having hit the marketplace in March itself. This may indicate the marketplace will function with about the equal variety of key players going forward.

3. India -- A Bellwether for Global Generic GLP-1 Rollout

India is the primary fundamental market wherein Novo Nordisk faces established competition for semaglutide -- the lively aspect in Ozempic and Wegovy. This makes India a capacity bellwether for the way the rollout could unfold globally.

Here is the worldwide image:

Canada permitted generics last month, though commercial launch timing stays uncertain

China expects conventional Ozempic to be behind schedule till subsequent yr despite the drug losing patent protection underneath the China--Switzerland Free Trade Agreement

So what happens in India can be watched intently through pharma groups and regulators around the arena.

4. Nationwide Chemist Strike on May 20 -- Full Preparations Underway

This is critical news for each affected person in India.

The All India Organisation of Chemists and Druggists (AIOCD) has finalized arrangements for a nationwide one-day shutdown on May 20, 2026. More than 12.40 lakh chemists and drug vendors throughout the united states are predicted to participate in the agitation.

Why are chemists protesting?

Let me list the primary reasons primarily based on the memorandums submitted to the Prime Minister:

First, unregulated on-line pharmacies. The AIOCD alleges that e-pharmacy structures are taking gain of regulatory relaxation. Medicines are being bought with out physical verification of prescriptions, allowing repeated use of the identical prescription.

Second, AI-generated faux prescriptions. The institutions claimed that AI-generated fake prescriptions should provide uncontrolled get entry to to antibiotics and habit-forming tablets, contributing to antimicrobial resistance -- a chief public fitness danger.

Third, deep discounting practices. Large corporate entities are annoying the pharmaceutical marketplace via deep discounting. While margins on vital drug treatments are constant via the government below NPPA and DPCO norms, those entities are creating unfair opposition.

Fourth, risk to livelihoods. The institutions alleged that unregulated e-pharmacies and deep discounting practices have put at chance the livelihoods of almost five crore dependents linked to the pharmaceutical exchange.

What unique needs had been made?

The AIOCD has demanded the withdrawal of key government notifications:

GSR 817 (August 20, 2018) -- which granted permission for on-line sale of medicines

GSR 220 (March 26, 2020) -- which allowed doorstep delivery of drug treatments at some stage in COVID-19

The institutions argue that GSR 220 was meant simplest as a brief COVID-19 measure, however digital systems keep to apply it to skip safeguards under Drug Rule 65.

5. Assam Opts Out -- A Surprising Twist

In a stunning improvement, the Assam Chemists and Druggists Association determined to choose out of the nationwide shutdown.

According to reports, pharmacies in Assam will stay open on May 20. The nation-stage frame determined no longer to take part inside the bandh, though the reasons had been now not right away clean.

This approach that at the same time as most of India will see closed chemist shops on May 20, patients in Assam will nonetheless have get right of entry to to drugs.

6. Telangana Chemists Confirm Participation

On the other hand, the Telangana Chemists and Druggists Association (TTCDA) showed that all chemists throughout the kingdom will be part of the nationwide shutdown.

In a memorandum submitted to Prime Minister Narendra Modi, the companies said repeated representations to the Centre over issues affecting the pharmaceutical exchange had failed to yield any concrete motion, main to developing resentment amongst chemists national.

The TTCDA also raised worries over the alleged misuse of regulatory relaxations by e-pharmacy platforms and AI-generated faux prescriptions.

7. Karnataka Chemists Join Strike -- Hospitals Exempted

In Karnataka's Dakshina Kannada district, clinical stores (with the exception of health center and clinical pharmacies) will stay closed on May 20 in support of the nationwide strike.

Arun Shetty, president of the South Kanara Chemists and Druggists Association, addressed press individuals and defined the demands. He said that drugs are not everyday commodities and require strict law and accountable doling out.

He also expressed issue over the growing misuse of scheduled and narcotic medicines by youths thru on-line structures. "In many times, tries have reportedly been made you bought such drug treatments the use of manipulated or AI-generated prescriptions," he said.

However, hospital and clinical pharmacies will characteristic as common, and emergency drug treatments can be made to be had on the day of the strike. "Pharmacists, as responsible healthcare experts, continue to be committed to presenting such drugs simplest after right verification and against actual prescriptions within the hobby of protecting society and public health," Shetty stated.

8. Key Regulatory Updates: FDA Shifts Under Makary's Era

Former FDA Commissioner Marty Makary, MD, MPH, has officially resigned following months of political strain and internal conflict surrounding vaccine coverage, flavored vape approvals, and broader FDA regulatory choices.

Here are five key regulatory shifts from Makary's era with the intention to effect drug approvals going ahead:

1. Ended the 2-Trial Standard for Drug Approvals

The FDA announced that going ahead, the default position is that 1 ok and well-controlled take a look at, combined with confirmatory evidence, will function the premise for marketing authorization of novel products. The FDA mentioned that roughly 60% of first-in-elegance pills approved inside the beyond five years were already cleared primarily based on a unmarried study, mainly in oncology and rare sicknesses.

2. Pushed to Accelerate Biosimilar Competition

Under the updated framework, developers may rely more closely on comparative analytical assessments, pharmacokinetic similarity research, and immunogenicity statistics to illustrate biosimilarity, reducing the want for big, useful resource-extensive efficacy trials. The FDA said this shift ought to notably decrease development costs, regularly estimated at $100 million to $300 million, and shorten timelines that usually span 6 to nine years.

3. Commissioner's Priority Voucher Program Accelerated Reviews

In June 2025, the FDA launched a concern voucher application that uses a multidisciplinary "tumor board-fashion" overview procedure and offers superior conversation and rolling overview to taking part agencies.

4. Integrated AI into FDA Drug Review

In October 2025, the FDA released a generative AI device known as "Elsa" that is already being used to accelerate obligations which include detrimental occasion summarization, label comparisons, and prioritization of inspection targets. The device is powered by a large language model and is intended to help personnel read, write, and synthesize large volumes of regulatory information more speedy.

5. Revised COVID-19 Vaccine Recommendations for Lower-Risk Groups

The FDA shifted away from broad booster guidelines, supporting boosters by and large for adults over sixty five and individuals with hazard elements for excessive disease.

9. Major Drug Approvals and Launches (Q1 2026)

The first area of 2026 saw numerous wonderful FDA approvals so one can effect affected person care:

Once-Weekly Basal Insulin for Type 2 Diabetes

On March 26, 2026, Novo Nordisk announced FDA approval of insulin icodec-abae (Awiqli) for improving glycemic manipulate in adults with type 2 diabetes. Based at the ONWARDS section 3a application, once-weekly insulin icodec tested reductions in HbA1c corresponding to daily basal insulin. This approval marks the first once-weekly basal insulin to be had in the US.

High-Dose Semaglutide 7.2 mg for Obesity

On March 19, 2026, Novo Nordisk introduced FDA approval of semaglutide 7.2 mg (Wegovy HD) for chronic weight control in adults with weight problems who require additional weight loss after tolerating the two.4-mg dose. Based on effects from the STEP UP scientific trial software, semaglutide 7.2 mg done a mean weight reduction of 20.7% over seventy two weeks, with about one-third of participants accomplishing ≥25% weight reduction.

First Oral IL-23 Receptor Antagonist for Plaque Psoriasis

On March 18, 2026, Johnson & Johnson announced FDA approval of the primary oral IL-23 receptor antagonist for mild-to-extreme plaque psoriasis, offering a new non-biologic option for patients.

First "Smart Capsule" for Obesity

On February 23, 2026, Allurion announced FDA premarket popularity of the Allurion Gastric Balloon System. The swallowable, fluid-filled "Smart Capsule" is positioned without endoscopy or anesthesia and self-empties after about 4 months, doing away with the need for elimination processes.

Dupilumab Approved for Allergic Fungal Rhinosinusitis

On February 25, 2026, Sanofi and Regeneron announced FDA approval of dupilumab (Dupixent) for the remedy of allergic fungal rhinosinusitis -- the first FDA-authorised remedy specially for AFRS.

10. Mergers and Acquisitions within the Pharma Sector

M&A hobby is surging in the pharmaceutical quarter as groups seek to benefit a aggressive part, boost up innovation, and pressure growth.

Key drivers of M&A pastime:

Pipeline diversification -- Companies are broadening their product services and mitigating risks tied to unmarried-drug portfolios

Accelerated time-to-marketplace -- Acquisitions bypass lengthy R&D levels

Cost synergies -- Shared sources and economies of scale lessen operational expenses

Access to emerging structures -- Particularly in biotech and AI-driven drug discovery

Risks related to M&A:

Regulatory hurdles -- Navigating complex regulatory frameworks can postpone deal finishing touch

Integration demanding situations -- Combining distinct groups brings cultural and operational conflicts

Market volatility -- Economic downturns and geopolitical occasions can appreciably impact deal value

Dilution of shareholder price -- Existing shareholders may additionally revel in reduced ownership chances

In the Indian context, Sun Pharma's $11.75 billion acquisition of Organon exemplifies this trend, as businesses are seeking to move from generics to distinctiveness prescribed drugs and extend globally.

11. Innovations and Research Breakthroughs

BioMed X and Servier Launch AI-Driven Antibody Engineering Team

BioMed X and French pharma giant Servier have released their first studies group in France to pioneer AI-pushed antibody engineering. The new group -- known as the ADB team (AI-Enabled Bispecific Antibody Design) -- is operating on growing an AI platform that integrates structural modeling, device mastering, and experimental validation to guide the rational design of bispecific antibodies.

GLP-1s May Improve Breast Cancer Survival Outcomes

New research posted in JAMA Network Open suggests that GLP-1 receptor agonists may be related to stepped forward survival outcomes and decreased recurrence risk among sufferers with breast most cancers. This provides to developing hobby surrounding the cures' capacity oncologic benefits.

12. Market Trends and Economic Impact

India Pharma Export Overview

India's pharmaceutical exports reached $30.4 billion in FY 2024-25, with the united states and Europe being the largest export locations. Exports span 200+ nations, and the bulk of exports fall underneath drug formulations and biologicals.

Positive Trade Balance

India's pharma imports stood at $8.9 billion, resulting in a positive trade balance of $21.5 billion. This surplus highlights the energy of India's pharmaceutical production abilities.

Global API Leadership

India manufactures 500+ Active Pharmaceutical Ingredients (APIs) and has 31% of global API production flowers positioned within the united states. This self-reliance in API production is a strategic gain.

FDI Inflows

The pharmaceutical zone is the ninth biggest phase in attracting FDI inflows till March 2025, reflecting global investor self belief in India's pharma ecosystem.

13. Challenges Facing the Indian Pharma Industry

Quality Control Issues

Despite incomes a excessive reputation for first-rate, there had been multiple times of drug recollects affecting both nearby and global markets. In some instances, it became found that positive companies have been generating counterfeit drugs bearing the names of famend pharmaceutical groups. The WHO revealed that cough syrups exported to Gambia through an Indian organisation had been of sub-general quality and had been linked to the deaths of over 60 youngsters.

Regulatory Harmonization

In the Indian regulatory system, the manufacturing, sale, and distribution of quality capsules have been entrusted to the CDSCO (critical level) and State-Level Authorities (SLAs). However, there are sometimes versions in the knowledge of the regulations, ensuing in differences in enforcing regulations. There is a need for periodic meetings among the CDSCO and SLAs to make sure uniformity in technique.

Intellectual Property Challenges

India's TRIPS-compliant patent legal guidelines save you the evergreening of safety, disallowing the new use of an present API beyond twenty years. While these laws strongly assist affordability via encouraging full of life price opposition, they do now not favor inventor-pleasant protections. Balancing innovation incentives with patient get right of entry to remains a mission.

US Tariff and Trade Uncertainties

Reports maintain to flow into about capacity price lists on pharmaceutical imports into the US. While no very last choice has been introduced, Indian pharma businesses are tracking the scenario intently. The US is India's biggest export marketplace for prescribed drugs, accounting for nearly forty% of overall pharma exports.

14. Global Collaborations and Partnerships

India's Global Pharma Leadership

India is the arena's biggest provider of regularly occurring drug treatments, accounting for 20% of the worldwide supply. The us of a is likewise a worldwide vaccine powerhouse, satisfying 60% of global demand and imparting vaccines to a hundred and fifty+ countries, together with 301 million COVID-19 doses to 101 countries with the aid of mid-2023. India stays a international chief in BCG, DPT, and measles vaccines.

Biosimilars Development

India is making sizable strides in biosimilars development, with over two hundred inside the pipeline. Reforms consisting of the 2019 New Drug and Clinical Trial Rules have streamlined regulatory timelines, whilst India's demographic variety and infrastructure electricity have made it the 3rd maximum favored destination for clinical trials globally.

Government Incentives

Key government schemes helping the pharmaceutical area consist of:

Production Linked Incentive (PLI) Scheme for Pharmaceuticals

PLI Scheme for Promotion of domestic manufacturing of vital APIs

Scheme for Promotion of Research and Innovation in Pharma MedTech Sector (PRIP)

Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)

15. Spotlight on Leading Pharma Companies

Sun Pharma

Sun Pharma's $11.75 billion acquisition of Organon marks the largest pharma acquisition with the aid of an Indian employer. The deal offers Sun Pharma get right of entry to to women's fitness medicines, presence in 140+ countries, and access into the biosimilars marketplace. The organization is transferring from generics to uniqueness prescription drugs.

Torrent Pharmaceuticals

Torrent has emerged as the leader inside the normal semaglutide race with a 38% market percentage. The organisation's manufacturers Semalix and Sembolic amassed ₹17 crore in income in April by myself.

Natco Pharma

Natco stays a high-margin however risky business. The business enterprise's earnings rely on restrained opportunities -- after they have exclusivity on a product, margins are awesome. When opposition enters, margins compress. The demerger of its agrochemical commercial enterprise is anticipated to unlock value for shareholders.

Indian Companies in Global Rankings

India has nine of the world's top 25 common manufacturers. The us of a produces 60,000 generic brands throughout 60 healing classes. With ninety four,000+ clinical trials registered by means of 2025, India is the third maximum favored vacation spot for scientific trials globally.

What This Means for You

Let me spoil it down with the aid of who you are.

If you're a affected person:

The chemist strike on May 20 is confirmed. Buy your vital drug treatments earlier than that date.

Hospital and scientific pharmacies will stay open -- emergency offerings may be to be had.

GLP-1 weight reduction capsules are becoming more low-priced with widely wide-spread variations now to be had.

Always buy from licensed pharmacies. Be aware of the dangers of fake and unregulated on-line drug treatments.

If you are an investor:

The GLP-1 market in India is exploding -- from ₹a hundred and forty crore to ₹1,400+ crore in 365 days.

Torrent Pharmaceuticals is main the regular semaglutide race with 38% market percentage.

Innovator brands (Novo Nordisk, Eli Lilly) are retaining their floor in spite of ordinary competition.

India is a bellwether for global GLP-1 familiar rollout -- watch this space.

If you're a pharma expert:

The chemist strike on May 20 will have an effect on distribution across most of India (except Assam).

AI-generated fake prescriptions are a new difficulty for regulators.

Drug safety and antimicrobial resistance continue to be key public fitness priorities.

Quality manage and regulatory harmonization are ongoing challenges for the enterprise.

FAQ -- Pharma News Weekly India

Q: What are the pinnacle pharmaceutical developments for 2026?

A: Based on this week's news: Explosive growth within the GLP-1 weightloss drug market (tenfold increase in 12 months). Generic competition reshaping marketplace dynamics at the same time as innovators maintain floor via pricing techniques. AI-driven drug discovery accelerating. Ongoing debate around online pharmacy law. Chemist strikes highlighting anxiety between conventional retail and e-pharma. Increasing focus on drug protection and antimicrobial resistance. Consolidation through M&A as Indian pharma movements from generics to area of expertise.

Q: What are the state-of-the-art pharma news updates this week (10-16 May 2026)?

A: Key updates include: GLP-1 market jumped tenfold to ₹1,408 crore. Generic semaglutide income volume up 242% to 137,000 units. Torrent leads accepted race with 38% proportion. Nationwide chemist strike showed for May 20. Assam opted out of the bandh. FDA accredited once-weekly insulin and excessive-dose semaglutide. Former FDA Commissioner Marty Makary resigned. India's pharma exports reached $30.4 billion in FY25.

Q: Where can I find all weekly pharma industry news?

A: For complete, curated weekly updates covering coverage modifications, market tendencies, and corporation-unique news in the Indian pharmaceutical region, you can depend upon Greencrossindia.com/blog.

Q: What is going on inside the pharmaceutical enterprise this week?

A: The industry is navigating a couple of developments. The GLP-1 market is exploding with popular variations making weight-loss tablets affordable to millions. Chemists are getting ready for a nationwide strike on May 20 over unregulated on line pharmacies and deep discounting. Assam has opted out of the strike, however most different states are collaborating. Global regulatory information consists of FDA approvals for once-weekly insulin and the resignation of the FDA Commissioner.

Q: Why is the chemist strike going on on May 20?

A: Chemists are protesting in opposition to unregulated on line pharmacies, sale of drug treatments with out proper prescription verification, AI-generated fake prescriptions, deep discounting practices through huge company entities, and the government's failure to withdraw emergency COVID-19 notifications (GSR 220 and GSR 817) that allowed doorstep medicine delivery.

Weekly Summary -- Key Takeaways

Let me speedy wrap up this week's Pharma News India Weekly:

First, the GLP-1 weightloss drug market in India has exploded -- from ₹140 crore to ₹1,408 crore in only one year, a tenfold increase.

Second, customary semaglutide income quantity jumped 242% to 137,000 units in April, whilst innovator manufacturers additionally grew 40% after fee cuts.

Third, Torrent Pharmaceuticals leads the general semaglutide race with 38% marketplace percentage, observed by means of Eris, Alkem, and MSN.

Fourth, India is a bellwether for international customary GLP-1 rollout -- what occurs right here will be watched global.

Fifth, the nationwide chemist strike on May 20 has been showed, with over 12 lakh shops predicted to remain closed across the united states.

Sixth, in a surprising twist, Assam chemists determined to opt out of the bandh -- pharmacies will stay open in the country.

Seventh, AI-generated faux prescriptions and antimicrobial resistance are emerging as new issues inside the online pharmacy debate.

Eighth, India's pharma exports reached $30.4 billion in FY25, with the USA being the biggest vacation spot.

Ninth, India debts for 20% of world frequent supply and 60% of world vaccines.

Tenth, the FDA accepted as soon as-weekly basal insulin, high-dose semaglutide, and the primary oral IL-23 receptor antagonist for psoriasis.

Eleventh, former FDA Commissioner Marty Makary resigned after imposing key regulatory shifts together with finishing the 2-trial trendy and integrating AI into drug evaluation.

Twelfth, nice manage and regulatory harmonization remain key challenges for the Indian pharmaceutical industry.

Conclusion and Future Outlook

This week certainly indicates that the Indian pharmaceutical industry is at an interesting crossroads.

We are seeing:

Explosive market boom -- the GLP-1 market has grown tenfold in one year

Intense competition -- generics vs innovators, on-line vs offline

Regulatory challenges -- the chemist strike highlights unresolved policy problems

Global implications -- India is a bellwether for the sector

M&A transformation -- Indian pharma is moving from generics to specialty

Innovation acceleration -- AI and biosimilars are reshaping drug improvement

The chemist strike on May 20 is a reminder that the shift to online pharmacies isn't with out friction. Patient protection, honest opposition, and clear regulation are all crucial.

If you are a patient who relies upon on regular drug treatments, please inventory up a few days before May 20. Hospital and medical pharmacies will stay open, however it's far higher to be organized.

Looking in advance, the Indian pharmaceutical industry is poised for persevered growth. With sturdy government assist via PLI schemes, increasing R&D funding, and expanding international footprints, Indian pharma organizations are properly-located to seize a bigger percentage of the worldwide market.

If you want to stay up to date with the modern pharmaceutical news, hold following this weekly series.

For greater updates, visit Greencrossindia.com/blog regularly.

That is all for this week, oldsters.

Found this useful? Share it with a colleague or pal who follows the pharma industry.

Got questions? Drop a remark underneath.

See you subsequent week with more updates. Until then, take care!

Chat With Us On Whatsapp For Pcd Pharma Franchise

Disclaimer: This article is for informational purposes simplest. The records is primarily based on publicly to be had assets such as information websites, magazines, and industry insights. Readers are cautioned to verify information independently earlier than making any decisions associated with fitness, commercial enterprise, or investment. Neither the writer nor Greencrossindia.com is answerable for any errors, omissions, or results springing up from the usage of this information.